Phase 2 psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase 2 is a registry phase value. Studies in larger groups that look at dosing and early signals while continuing to monitor tolerability. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 323 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 138 |
| MDMA | 42 |
| LSD | 10 |
| DMT | 6 |
| 5-MeO-DMT | 4 |
| Ayahuasca | 3 |
| Ketamine | 131 |
| Ibogaine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 89 | 28% |
| Not yet recruiting | 31 | 10% |
| Enrolling by invitation | 3 | 1% |
| Active, not recruiting | 19 | 6% |
| Completed | 113 | 35% |
| Terminated | 22 | 7% |
| Suspended | 1 | 0% |
| Withdrawn | 21 | 7% |
| Status not reported | 24 | 7% |
Countries
Country is taken from the study's linked research site. 8 of 323 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 202 | 63% |
| Canada | 42 | 13% |
| Switzerland | 12 | 4% |
| Israel | 6 | 2% |
| Brazil | 5 | 2% |
| Netherlands | 5 | 2% |
| Sweden | 5 | 2% |
| Australia | 4 | 1% |
| Belgium | 4 | 1% |
| Germany | 4 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 144 |
| 2020 to 2023 | 85 |
| 2015 to 2019 | 48 |
| 2010 to 2014 | 36 |
| Before 2010 | 10 |
Study design
- 323 interventional and 0 observational studies.
- Median planned or actual enrolment is 40 participants (range 1 to 480, across 303 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 128 |
| Trauma and PTSD | 57 |
| Alcohol use | 25 |
| Other substance use | 23 |
| Cancer and end of life | 22 |
| Suicidal thoughts | 21 |
| Anxiety | 16 |
| Pain and headache | 10 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT06005662 | Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Withdrawn | Phase 2 | United States | 2027-04 |
| NCT07774702 | Psilocybin for Methamphetamine Use Disorder | Not yet recruiting | Phase 2 | United States | 2027-02 |
| NCT07566104 | Group PACBT for Depression | Not yet recruiting | Phase 2 | United States | 2027-01 |
| NCT07852832 | Effects of Psilocybin on Craving in Nicotine Dependence | Not yet recruiting | Phase 2 | Not reported | 2027-01 |
| NCT07768618 | Electrophysiologic Mechanisms of Ketamine Antidepressant Response | Not yet recruiting | Phase 2 | United States | 2026-12 |
| NCT07792538 | Psilocybin-Assisted Psychotherapy for Veterans With PTSD | Not yet recruiting | Phase 2 | Netherlands | 2026-12 |
| NCT07756736 | Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Not yet recruiting | Phase 2 | United States | 2026-11 |
| NCT07765693 | MDMA-AT for PTSD in Young Adults With Childhood Trauma | Not yet recruiting | Phase 2 | United States | 2026-10 |
| NCT07791901 | MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial | Not yet recruiting | Phase 2 | Canada | 2026-10 |
| NCT07704762 | Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder | Not yet recruiting | Phase 2 | Not reported | 2026-10 |
| NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Recruiting | Phase 2 | United States | 2026-10 |
| NCT07868913 | Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07570654 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07801703 | Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07745569 | Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | Not yet recruiting | Phase 2 | United States | 2026-08 |
| NCT06885996 | Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | Not yet recruiting | Phase 2 | Canada | 2026-08 |
| NCT07562191 | Inhaled DMT for Major Depressive Disorder | Recruiting | Phase 2 | Brazil | 2026-08 |
| NCT07479550 | Anesthesia-Masked Psilocybin Therapy for Major Depression | Not yet recruiting | Phase 2 | United States | 2026-07 |
| NCT07306364 | Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | Not yet recruiting | Phase 2 | United States | 2026-06 |
| NCT07565909 | Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | Not yet recruiting | Phase 2 | United States | 2026-06 |
| NCT07569198 | Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | Recruiting | Phase 2 | Canada | 2026-06 |
| NCT07582120 | Psilocybin-Assisted Therapy as a Treatment for Depression | Not yet recruiting | Phase 2 | United States | 2026-06 |
| NCT07639359 | Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | Recruiting | Phase 2 | United States | 2026-05 |
| NCT07227909 | NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy | Not yet recruiting | Phase 2 | United States | 2026-05 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 3 | Phase 4 | Phase not applicable